[Natural history of metastasic prostate cancer treated with androgen deprivation therapy and secondary hormonal therapy efficiency].
OBJECTIVE
to analyze metastatic prostate cancer progression in patients treated with hormonal blockade as well as second line hormonal treatments outcomes.


METHODS
199 metastatic patients were selected from a 455 hormonal treated patients pool. Time to biochemical progression was studied with Kaplan Meier analysis and patients were stratified according to pathological differentiation. Second line treatment lasting and efficacy were also assessed.


RESULTS
74 patients out of 192 metastatic patients (56.1%) progressed in terms of PSA. Median time to biochemical progression was 1.7 years (1.2-2.3, CI 95%). We did not find stadistical differences on pathological differentiation (p = 0.238). Second line treatment's efficacy, applied to 41 patients was 34.1%, without any stadistical differences among these treatments. Response treatment median time was 6.8 months without stadistical differences among different treatments (p = 0.220).


CONCLUSIONS
hormonal blockade efficacy in metastatic prostate cancer has a limited value in time in our experience. One third of these patients have a limited response to a second line treatment although this response is even shorter in duration.
Rodriguez García
N
N
Servicio Urología Hospital Universitario de Getafe, Madrid. nuriaroga8@yahoo.es
Luján Galán
M
M
Pascual Mateo
C
C
García Tello
A M
AM
Torres Zambrano
G M
GM
Berenguer Sánchez
A
A
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D012189:Retrospective Studies
D000726:Androgen Antagonists